(GNOM) Genomics & Biotechnology - Overview
Etf: Biotech, Genomics, Pharmaceutical, Healthcare
Dividends
| Dividend Yield | 1.40% |
| Yield on Cost 5y | 0.08% |
| Yield CAGR 5y | 178.20% |
| Payout Consistency | 32.5% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.9% |
| Relative Tail Risk | -0.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.50 |
| Alpha | -2.41 |
| Character TTM | |
|---|---|
| Beta | 1.073 |
| Beta Downside | 0.937 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.67% |
| CAGR/Max DD | -0.07 |
Description: GNOM Genomics & Biotechnology December 30, 2025
The Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) commits at least 80% of its assets to the Solactive Genomics & Biotechnology Index, targeting exchange-listed firms that stand to profit from breakthroughs in genomic science and biotech applications. The fund is classified as a non-diversified health-sector ETF domiciled in the United States.
Key industry drivers include accelerating CRISPR adoption (global market projected to exceed $30 billion by 2028), rising R&D intensity-average biotech firms now allocate ~20% of revenue to research-and robust capital inflows, with biotech venture capital funding up ~12% YoY in Q3 2024. GNOM’s top holdings are weighted toward large-cap innovators such as Illumina, CRISPR Therapeutics, and Moderna, which together account for roughly 35% of the portfolio.
For a deeper quantitative view, consider reviewing ValueRay’s analytics dashboard to compare GNOM’s risk-adjusted performance against peer ETFs.
What is the price of GNOM shares?
Over the past week, the price has changed by -3.75%, over one month by -2.88%, over three months by +8.49% and over the past year by +21.29%.
Is GNOM a buy, sell or hold?
What are the forecasts/targets for the GNOM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 49.7 | 7.7% |
GNOM Fundamental Data Overview February 05, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 52.3m USD (52.3m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 52.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 52.3m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.87% (E(52.3m)/V(52.3m) * Re(9.87%) + (debt-free company))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)